Pfizer

May 22, 2019May 22, 2019

Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows

News

Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological imaging — or death in metastatic hormone-sensitive prostate cancer (mHSPC) patients, a Phase 3 clinical trial shows. ... Read more

May 16, 2019

Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests

News

Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were ... Read more

March 4, 2019March 4, 2019

Xtandi, Zytiga Better for African-Americans Than Whites With Advanced Prostate Cancer, Research Finds

News

African-Americans with metastatic castration-resistant prostate cancer live longer after treatment with the androgen inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide) than white men, a new study reports. Historically, African-Americans diagnosed ... Read more

February 14, 2019

Xtandi Delays Disease Progression, Death in Metastatic Hormone-Sensitive PC Patients, Trial Shows

News

Adding the androgen receptor inhibitor Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression — assessed through radiological imaging — or death among metastatic hormone-sensitive prostate cancer patients, results ... Read more

February 12, 2018February 13, 2018

Xtandi Reduces Risk of Metastasis in Castration-resistant Prostate Cancer, Phase 3 Trial Shows

News

Treatment with Xtandi (enzalutamide) reduced the risk of metastasis or death in castration-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond the prostate, Pfizer and Japan-based Astellas Pharma recently ... Read more

June 13, 2017June 13, 2017

Changes Made to Phase 3 Xtandi Trial in Men with Non–Metastatic Castration–Resistant Prostate Cancer

News

Astellas Pharma and Pfizer amended the protocol of the international Phase 3 PROSPER trial evaluating Xtandi (enzalutamide) in men with non–metastatic castration–resistant prostate cancer (CRPC). PROSPER is a randomized, double–blind, placebo–controlled trial (NCT02003924) that is evaluating the ... Read more

December 19, 2016December 19, 2016

Xtandi Combo Fails to Improve Survival in Advanced Prostate Cancer Patients in Phase 4 Study

News

Pfizer and Astellas Pharma announced that a Phase 4 clinical trial, investigating longer-term use of Xtandi (enzalutamide) as a combination treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), did not reach its primary goal ... Read more